强化瑞舒伐他汀治疗对急性冠脉综合征患者PCI术后hsCRP的影响

目的:观察强化瑞舒伐他汀治疗对急性冠脉综合征患者经皮冠状动脉介入治疗(PCI)术后不同时间点高敏C反应蛋白(hsCRP)的影响。方法:选择2011年7月~2012年6月在我院诊断为急性冠脉综合征患者86例,随机分为2组。强化组于PCI术前服用瑞舒伐他汀20 mg/d,术后持续1周,1周后减量为10 mg/d。对照组PCI术前术后均为10 mg/d。分别于术前、术后1 d、术后1周,术后1个月检测患者血浆中hsCRP的变化。结果:强化组患者PCI术后1 d、术后1周血浆hsCRP的水平明显低于对照组,而PCI术后1个月两组患者血浆hsCRP的水平无显著差异。结论:PCI术前及术后1周应用瑞舒伐他汀20 mg/d较10 mg/d能够明显降低血浆hsCRP水平,且安全性良好。

Effects of rosuvastatin on hsCRP in patients with acute coronary syndrome undergoing percutaneous coronary intervention

AIM: To study the effects of rosuvastain at different dosages on serum high-sensitivity C-reactive protein(hsCRP) in patients with acute coronary syndrome undergoing percutaneous coronary intervention(PCI).METHODS: Fifty-eight patients were randomly divided into two groups: experimental group was given rosuvastain 20 mg/day before PCI and 1 week after PCI and control group was given rosuvastain(10 mg/day) before and after PCI.Serum hsCRP at different time points(before PCI,1 day after PCI,1 week after PCI and 1 month after PCI) was detected.RESULTS: One day and one week after PCI,serum hsCRP level of patients in experimental group was significantly lower than that in control group(P<0.01) but no significant difference in serum hsCRP was seen at 1 month after PCI.CONCLUSION: Rosuvastain at the dosage of 20 mg/day before PCI and 1 week after PCI can better decrease the level of serum hsCRP than rosuvastain at the dosage of 10 mg/day in patients with acute coronary syndrome undergoing PCI.